$33.5MSeries B, 12 January 2026
Series B advances the pipeline including Phase 1 muscle-regeneration candidate JUV-161.
- Amount
- $33.5M
- Stage
- Series B
- Announced
- 12 January 2026
- Lead
- Bison Ventures
- Other investors
- Eli Lilly and Company, Jefferson Life Sciences, Mubadala Capital, Manta Ray
- Use of funds
- Series B advances the pipeline including Phase 1 muscle-regeneration candidate JUV-161.
- Checked
- Amount and date checked against the press source
- Source
- Juvena Therapeutics: $33.5 Million Series B Raised To Advance Regenerative Biologics Pipeline pulse2.com